CN113164595A - 抗人cd45rc抗体及其用途 - Google Patents

抗人cd45rc抗体及其用途 Download PDF

Info

Publication number
CN113164595A
CN113164595A CN201980076451.4A CN201980076451A CN113164595A CN 113164595 A CN113164595 A CN 113164595A CN 201980076451 A CN201980076451 A CN 201980076451A CN 113164595 A CN113164595 A CN 113164595A
Authority
CN
China
Prior art keywords
seq
antibody
binding fragment
lcvr
hcvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980076451.4A
Other languages
English (en)
Chinese (zh)
Inventor
C·吉永瑙
I·阿内贡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Centre Hospitalier Universitaire de Nantes
Nantes Université
Original Assignee
Universite de Nantes
Institut National de la Santé et de la Recherche Médicale
Centre Hospitalier Universitaire de Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Nantes, Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Universitaire de Nantes filed Critical Universite de Nantes
Publication of CN113164595A publication Critical patent/CN113164595A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980076451.4A 2018-09-21 2019-09-20 抗人cd45rc抗体及其用途 Pending CN113164595A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306230.6A EP3626265A1 (en) 2018-09-21 2018-09-21 Anti-human cd45rc antibodies and uses thereof
EP18306230.6 2018-09-21
PCT/EP2019/075374 WO2020058495A1 (en) 2018-09-21 2019-09-20 Anti-human cd45rc antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CN113164595A true CN113164595A (zh) 2021-07-23

Family

ID=63713787

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980076451.4A Pending CN113164595A (zh) 2018-09-21 2019-09-20 抗人cd45rc抗体及其用途

Country Status (13)

Country Link
US (2) US12168694B2 (cg-RX-API-DMAC7.html)
EP (2) EP3626265A1 (cg-RX-API-DMAC7.html)
JP (2) JP7796531B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210070303A (cg-RX-API-DMAC7.html)
CN (1) CN113164595A (cg-RX-API-DMAC7.html)
AU (1) AU2019343746C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021005276A2 (cg-RX-API-DMAC7.html)
CA (1) CA3113562A1 (cg-RX-API-DMAC7.html)
IL (1) IL281608B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021003281A (cg-RX-API-DMAC7.html)
NZ (1) NZ774030A (cg-RX-API-DMAC7.html)
SG (1) SG11202102659RA (cg-RX-API-DMAC7.html)
WO (1) WO2020058495A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3626265A1 (en) * 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
US20230147657A1 (en) * 2020-03-20 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Chimeric antigen receptor specific for human cd45rc and uses thereof
PL4401842T3 (pl) * 2021-09-16 2025-11-24 Aboleris Pharma Domeny wiążące przeciwko ludzkiemu CD45RC i ich zastosowania
CA3240875A1 (en) 2021-12-23 2023-06-29 Stefanie Urlinger Discernible cell surface protein variants of cd45 for use in cell therapy
EP4637928A1 (en) 2022-12-23 2025-10-29 Cimeio Therapeutics AG Antibodies targeting cd45

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016016442A1 (en) * 2014-08-01 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
CN107849141A (zh) * 2015-07-16 2018-03-27 Ucb生物制药私人有限公司 结合cd45的抗体分子

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド N末端にアミノ安息香酸単位を有するオーリスタチン
EP1898529A1 (en) 2005-06-28 2008-03-12 Pioneer Corporation Broadcast receiving apparatus, interference detecting apparatus and interference detecting method
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
AU2006294644A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
ES2642787T3 (es) 2005-10-21 2017-11-20 Lfb Usa, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
FR3003171B1 (fr) 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
EP3626265A1 (en) * 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016016442A1 (en) * 2014-08-01 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
CN107849141A (zh) * 2015-07-16 2018-03-27 Ucb生物制药私人有限公司 结合cd45的抗体分子

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELODIE PICARDA ET AL: "Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells", JCI INSIGHT, vol. 2, no. 3, 9 February 2017 (2017-02-09), pages 1, XP055601701, DOI: 10.1172/jci.insight.90088 *
刘彤等: "大鼠小肠移植后外周血CD45RC~+细胞和CD45RC~-细胞比值的变化及意义", 中华器官移植杂志, vol. 26, no. 07, 20 January 2006 (2006-01-20), pages 404 - 407 *

Also Published As

Publication number Publication date
BR112021005276A2 (pt) 2021-07-13
IL281608B1 (en) 2025-12-01
US20220033500A1 (en) 2022-02-03
WO2020058495A1 (en) 2020-03-26
MX2021003281A (es) 2021-08-11
AU2019343746C1 (en) 2026-04-02
SG11202102659RA (en) 2021-04-29
JP7796531B2 (ja) 2026-01-09
US20250122300A1 (en) 2025-04-17
CA3113562A1 (en) 2020-03-26
AU2019343746A1 (en) 2021-04-15
IL281608B2 (en) 2026-04-01
IL281608A (en) 2021-05-31
AU2019343746B2 (en) 2025-12-04
JP2022502024A (ja) 2022-01-11
KR20210070303A (ko) 2021-06-14
NZ774030A (en) 2026-03-27
JP2025164963A (ja) 2025-10-31
EP3852802A1 (en) 2021-07-28
US12168694B2 (en) 2024-12-17
EP3626265A1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
KR102761792B1 (ko) B7-h4 항체 및 그의 사용 방법
KR101527297B1 (ko) 4-1bb 결합 분자
TWI915520B (zh) 含抗tslp抗體的藥物組合物
KR102405278B1 (ko) Alk7 결합 단백질 및 이들의 용도
KR20210070303A (ko) 항-인간 cd45rc 항체 및 이의 용도
JP2004531263A (ja) 特異的結合タンパク質およびその使用
KR20200085940A (ko) 시알릴-루이스 a에 대한 사람 항체 코드화 핵산
KR20200123170A (ko) B7-h4 항체 제형
KR20200067144A (ko) 트랜스타이레틴의 검출 방법
CN112574313B (zh) 抗cd73抗体及其用途
CN111868089B (zh) B7-h4抗体给药方案
KR20160131082A (ko) Lg1-3에 특이적인 항-라미닌4 항체
CN112552406B (zh) 抗人cd73抗体
EP4393949A1 (en) Pharmaceutical composition containing fusion protein
RU2826421C2 (ru) Выделенное антитело к CD45RC человека, нуклеиновая кислота, вектор экспрессии, клетка, фармацевтическая композиция, их применение, in vitro способ обнаружения hCD45RC
HK40097033B (en) Pharmaceutical composition containing anti-tslp antibody
HK40097033A (zh) 含抗tslp抗体的药物组合物
HK40091337A (en) Antibodies against interleukin-22
HK40036127B (zh) B7-h4抗体给药方案
HK40027698B (en) B7-h4 antibodies and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination